Friday, 16 October 2026European Markets

SES IMAGOTAG Stock Was Up By 16.67% On Monday

Loading stream...

(vianews) - the market ended the session with ses imagotag (sesl.pa) jumping 16.67% to €81.20 on monday while cac 40 rose 0.29% to €7,184.35.

ses imagotag's last close was €69.60, 59.95% under its 52-week high of €173.80.

about ses imagotag

ses-imagotag société anonyme installs and maintains electronic shelf labels worldwide. the company offers internet of things (iot) devices, including electronic shelf labels, cameras, fixtures and accessories, infrastructure, wi-fi integrations, and captana wireless mini cameras; and retail iot saas solutions comprising vusion cloud, vusion asset management, vusion manager, vusion studio, vusion link, vusion engage, storefront, vusion rail, and vusion ads for brands. it also provides cloud platform solutions comprising pricing automation, shelf efficiency, enhance in-store shopping experience, and marketing; and vusion operating. the company serves various industries, such as grocery, fruits and vegetables, electronics, diy and furniture, pharmacy, cosmetics, fashion, digital signage, and industry. ses-imagotag société anonyme was founded in 1992 and is headquartered in nanterre, france.

earnings per share

as for profitability, ses imagotag has a trailing twelve months eps of €0.49.

pe ratio

ses imagotag has a trailing twelve months price to earnings ratio of 165.71. meaning, the purchaser of the share is investing €165.71 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.89%.

moving average

ses imagotag's value is way below its 50-day moving average of €147.63 and way below its 200-day moving average of €122.72.

revenue growth

year-on-year quarterly revenue growth grew by 52.2%, now sitting on 620.86m for the twelve trailing months.

more news about ses imagotag (sesl.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com